This Favorable Sign Appears On Bio-Techne’s Chart
If history is any guide, there may be good fortune ahead for shares of Bio-Techne (NASDAQ:TECH). A so-called…
This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts
U.S stocks closed higher on Friday, with the Dow Jones jumping more than 500 points during the session.
What 4 Analyst Ratings Have To Say About Bio-Techne
Within the last quarter, Bio-Techne (NASDAQ:TECH) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Bio-Techne: Q3 Earnings Insights
Bio-Techne (NASDAQ:TECH) reported its Q3 earnings results on Wednesday, May 3, 2023 at 06:30 AM. Here’s what investors…
Benchmark Maintains Buy on Bio-Techne, Maintains $120 Price Target
Benchmark analyst Robert Wasserman maintains Bio-Techne (NASDAQ:TECH) with a Buy and maintains $120 price target.
SVB Leerink Maintains Outperform on Bio-Techne, Lowers Price Target to $110
SVB Leerink analyst Puneet Souda maintains Bio-Techne (NASDAQ:TECH) with a Outperform and lowers the price target from $125 to $110.
Keybanc Maintains Overweight on Bio-Techne, Lowers Price Target to $115
Keybanc analyst Paul Knight maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target from $125 to $115.
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Benzinga’s Top Ratings Upgrades, Downgrades For January 10, 2023
Upgrades Morgan Stanley upgraded the previous rating for Stem Inc (NYSE:STEM) from Equal-Weight to Overweight. In the third…
Deutsche Bank Initiates Coverage On Bio-Techne with Buy Rating, Announces Price Target of $100
Deutsche Bank analyst Justin Bowers initiates coverage on Bio-Techne (NASDAQ:TECH) with a Buy rating and announces Price Target of $100.